Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

 Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

Shots:

  • The in-vivo study was evaluated on group of rabbits administering bilateral intravitreal injection of Xlucane (ranibisumab, Lucentis biosimilar) vs Lucentis divided in two equal groups, testing its PK and tolerability in both the serum and the eyeglass body
  • The results show Xlucane is well tolerated with no ocular inflammation in eyes, with equivalent PK observed in the serum and eyeglass body
  • Xlucane is a mAb, being developed as biosimilar of Lucentis. Lucentis is approved for the treatment of Diabetic Retinopathy & Macular Edema, mCNV, Wet AMD and Macular Edema Following RVO

Click here to read full press release/ article | Ref: Xbrane Biopharma | Image: Xbrane Biopharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post